At a glance
ClinicalIndex Comparison RecordN/ACompleted· 103 enrolled
Drug / intervention
Osilodrostatdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Retrospective Observational Study to Evaluate the Safety and Effectiveness of Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome (LINC7)
In Brief
An observational study evaluating Osilodrostat for Cushing's Syndrome. Completed, enrolled 103 participants across 1 site.
Detailed Summary
This is a multi-centre, observational, non-comparative, retrospective cohort study designed to evaluate the long-term safety and effectiveness of osilodrostat in non-CD CS patients. Patients treated with oral osilodrostat regardless of the duration of their treatment will be followed retrospectively for up to 36 months after initiating osilodrostat.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCushing's Syndrome
CountriesFrance
Collaborators--
Timeline
N/ACompletedFinished
2023202420252026
First PostedDec 2022
Enrollment StartJan 2023
Primary CompletionSep 2023
Study CompletionOct 2023
TodayJul 2026
First PostedDec 1, 2022
Enrollment StartJan 16, 2023
Primary CompletionSep 30, 2023
Study CompletionOct 30, 2023
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 3.6 years ago
Interventions
Osilodrostatdrug
oral administration